Insmed to Present at Upcoming Conferences
30 Octobre 2006 - 10:56PM
Business Wire
Insmed Incorporated (NASDAQ: INSM) today announced that Philip J.
Young, Chief Business Officer of Insmed Incorporated, will present
a corporate overview on Tuesday, October 31 at 10:30 AM ET during
the C.E. Unterberg, Towbin Life Sciences Conference taking place at
the New York Palace Hotel in New York City. He will also be
presenting on Monday, November 6 at 4:55 PM ET at the Rodman &
Renshaw 8th Annual Healthcare Conference at the New York Palace
Hotel in New York City; and on Tuesday, November 28 at 9:30 AM ET
at the Lazard Capital Markets 3rd Annual Life Sciences Conference,
which is also taking place at the New York Palace Hotel in New York
City. For more information and to access live audio webcasts,
please go to www.insmed.com. About Insmed Insmed is a
biopharmaceutical company focused on the discovery and development
of drug candidates for the treatment of metabolic diseases and
endocrine disorders with unmet medical needs. For more information,
please visit http://www.insmed.com. Forward Looking Statements
Statements included within this press release, which are not
historical in nature, may constitute forward-looking statements for
the purposes of the safe harbor provided by the Private Securities
Litigation Reform Act of 1995. Forward-looking statements in this
press release include, but are not limited to, statements regarding
the pending litigation and or future ability to conduct our
business as now conducted and as it is currently proposed to be
conducted. Such forward-looking statements are subject to numerous
risks and uncertainties, including but not limited to the
uncertainty of the outcome of any litigation with Tercica. We can
give no assurances that we would be successful in any litigation or
that such litigation would not have a material adverse effect on
our business, financial condition and results of operation.
Furthermore, we may not be able to afford the expense of defending
against such a claim. As a result of these and other risks and
uncertainties, actual results may differ materially from those
described in this press release. For further information with
respect to factors that could cause actual results to differ from
expectations, reference is made to reports filed by the Company
with the Securities and Exchange Commission under the Securities
Exchange Act of 1934, as amended. Insmed Incorporated (NASDAQ:
INSM) today announced that Philip J. Young, Chief Business Officer
of Insmed Incorporated, will present a corporate overview on
Tuesday, October 31 at 10:30 AM ET during the C.E. Unterberg,
Towbin Life Sciences Conference taking place at the New York Palace
Hotel in New York City. He will also be presenting on Monday,
November 6 at 4:55 PM ET at the Rodman & Renshaw 8th Annual
Healthcare Conference at the New York Palace Hotel in New York
City; and on Tuesday, November 28 at 9:30 AM ET at the Lazard
Capital Markets 3rd Annual Life Sciences Conference, which is also
taking place at the New York Palace Hotel in New York City. For
more information and to access live audio webcasts, please go to
www.insmed.com. About Insmed Insmed is a biopharmaceutical company
focused on the discovery and development of drug candidates for the
treatment of metabolic diseases and endocrine disorders with unmet
medical needs. For more information, please visit
http://www.insmed.com. Forward Looking Statements Statements
included within this press release, which are not historical in
nature, may constitute forward-looking statements for the purposes
of the safe harbor provided by the Private Securities Litigation
Reform Act of 1995. Forward-looking statements in this press
release include, but are not limited to, statements regarding the
pending litigation and or future ability to conduct our business as
now conducted and as it is currently proposed to be conducted. Such
forward-looking statements are subject to numerous risks and
uncertainties, including but not limited to the uncertainty of the
outcome of any litigation with Tercica. We can give no assurances
that we would be successful in any litigation or that such
litigation would not have a material adverse effect on our
business, financial condition and results of operation.
Furthermore, we may not be able to afford the expense of defending
against such a claim. As a result of these and other risks and
uncertainties, actual results may differ materially from those
described in this press release. For further information with
respect to factors that could cause actual results to differ from
expectations, reference is made to reports filed by the Company
with the Securities and Exchange Commission under the Securities
Exchange Act of 1934, as amended.
Insmed (NASDAQ:INSM)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Insmed (NASDAQ:INSM)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024